MedTrace Logo

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

NCT03423355 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-12-15

No results posted yet for this study

Summary

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Dapagliflozin (Forxiga®)

10mg p.o. daily

DRUG

Hydrochlorothiazide 25 mg

25mg p.o. daily

DRUG

Placebo matching Dapagliflozin

Placebo matching Dapagliflozin p.o. daily

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-03-31
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03423355 on ClinicalTrials.gov